NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
MOUNTAIN VIEW, Calif., March 27, 2024 (GLOBE NEWSWIRE) — NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming […]
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on […]
Lesaka to Host Webcast and Conference Call to Review Third Quarter 2024 Results
JOHANNESBURG, South Africa, March 27, 2024 (GLOBE NEWSWIRE) — Lesaka Technologies, Inc. (“Lesaka” or the “Company”) (NasdaqGS:LSAK; JSE: LSK) today […]
Rumble Reports Fourth Quarter and Full Year 2023 Results
~ Full Year 2023 Revenue Increased 106% to $81.0 Million ~ ~ Fourth Quarter Average Monthly Active Users Sequentially Increased […]
Zoomcar Partners with ACKO Drive; Empowers Local Hosts to Increase Car Fleet on its Car-Sharing Marketplace Platform
BENGALURU, India, March 27, 2024 (GLOBE NEWSWIRE) — Zoomcar Holdings, Inc. (“Zoomcar” or the “Company”) (Nasdaq: ZCAR), the NASDAQ-listed leading […]
Gaia Reports Fourth Quarter and Full Year 2023 Results
BOULDER, Colo., March 27, 2024 (GLOBE NEWSWIRE) — Gaia, Inc. (NASDAQ: GAIA) (“Gaia” or the “Company”), a conscious media and […]
Aqua Metals Advances Sierra-ARC Lithium Battery Recycling Campus and Secures Offtake Partnership; Reports Full-Year 2023 Financial Results
RENO, Nev., March 27, 2024 (GLOBE NEWSWIRE) — Aqua Metals, Inc. (NASDAQ: AQMS), a pioneer in sustainable lithium-ion battery recycling, […]
The Oncology Institute Reports Fourth Quarter and Full Year 2023 Financial Results and Guidance for 2024
CERRITOS, Calif., March 27, 2024 (GLOBE NEWSWIRE) — The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of […]
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the […]
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
SAN MATEO, Calif., March 27, 2024 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing […]
